ArticleBMJ open2024

Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol.

Krishna Tiwari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.